Heteropolymer-mediated clearance of immune complexes via erythrocyte CR1: mechanisms and applications

被引:54
作者
Lindorfer, MA
Hahn, CS
Foley, PL
Taylor, RP
机构
[1] Univ Virginia, Hlth Syst, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA
[2] Univ Virginia, Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA
[3] Univ Virginia, Hlth Syst, Beirne Carter Ctr Immunol Res, Charlottesville, VA 22908 USA
[4] Univ Virginia, Hlth Syst, Ctr Comparat Med, Charlottesville, VA 22908 USA
关键词
D O I
10.1034/j.1600-065x.2001.1830102.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Opsonization of particulate pathogens by antibodies and complement can lead to their binding to the complement receptor (CRI), specific for C3b, on primate erythrocytes (E). This process of immune adherence may play a role in immunologic defense by immobilizing bacteria and viruses, thus preventing them from leaving the bloodstream to invade susceptible tissue and organs. Immune adherence of C3b-opsonized and immune complexed pathogens to E may also facilitate their transfer to, and destruction by, fixed tissue macrophages. We have used mAbs specific for CRI crosslinked with pathogen specific mAbs to generate heteropolymers (HP) which can bind a wide range of substrates to primate erythrocytes. Both prototype and bonafide pathogens bound to primate E via HP are handled in the circulation of non-human primates in a manner which appears to be virtually identical to the mechanism by which C3b-opsonized substrates bound to E CR1 a-re cleared. In this process of focused phagocytosis, Fc receptors on the phagocytic cell engage the E-bound complex, CR I is removed by proteolysis, and the entire immune complex and CRI are internalized while sparing the E. It may be possible to use HP to target pathogens in the bloodstream in a wide range of therapeutic applications.
引用
收藏
页码:10 / 24
页数:15
相关论文
共 107 条
[51]   COMPLEMENT RECEPTOR (CR-1) DEFICIENCY IN ERYTHROCYTES FROM PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
IIDA, K ;
MORNAGHI, R ;
NUSSENZWEIG, V .
JOURNAL OF EXPERIMENTAL MEDICINE, 1982, 155 (05) :1427-1438
[52]   INVIVO HANDLING OF SOLUBLE COMPLEMENT-FIXING AB/DSDNA IMMUNE-COMPLEXES IN CHIMPANZEES [J].
KIMBERLY, RP ;
EDBERG, JC ;
MERRIAM, LT ;
CLARKSON, SB ;
UNKELESS, JC ;
TAYLOR, RP .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (03) :962-970
[53]   RECEPTORS FOR IMMUNOGLOBULIN-G - MOLECULAR DIVERSITY AND IMPLICATIONS FOR DISEASE [J].
KIMBERLY, RP ;
SALMON, JE ;
EDBERG, JC .
ARTHRITIS AND RHEUMATISM, 1995, 38 (03) :306-314
[54]   INTERLEUKIN-6 IN HUMAN MULTIPLE-MYELOMA [J].
KLEIN, B ;
ZHANG, XG ;
LU, ZY ;
BATAILLE, R .
BLOOD, 1995, 85 (04) :863-872
[55]  
Kuhn SE, 1998, J IMMUNOL, V160, P5088
[56]  
Lach-Trifilieff E, 1999, J IMMUNOL, V162, P7549
[57]  
LENNEK R, 1981, J IMMUNOL, V127, P602
[58]   A bispecific dsDNA x monoclonal antibody construct for clearance of anti-dsDNA IgG in systemic lupus erythematosus [J].
Lindorfer, MA ;
Schuman, TA ;
Craig, ML ;
Martin, EN ;
Taylor, RP .
JOURNAL OF IMMUNOLOGICAL METHODS, 2001, 248 (1-2) :125-138
[59]  
LISZEWSKI MK, 1998, HUMAN COMPLEMENT SYS, P149
[60]  
LIU C, 1995, BISPECIFIC ANTIBODIE, P133